ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Autoimmune Diseases
Cognitive Dysfunction
Neoplasm Metastasis

Multiple Sclerosis (MS) trials near Paris, Île-de-France, FRA:

Locations recently updated

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Le Kremlin Bicetre, France and 73 other locations

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Paris, France and 161 other locations

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Enrolling
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Créteil, France and 36 other locations

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Le Kremlin Bicetre, France and 107 other locations

This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis...

Active, not recruiting
Multiple Sclerosis
Clinically Isolated Syndrome
Drug: Ocrelizumab

Phase 4

Roche
Roche

Paris, France and 10 other locations

Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnorma...

Enrolling
Multiple Sclerosis, Relapsing-Remitting
Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
Drug: Placebo 4 mL Solution for Injection

Phase 2

University Hospital, Strasbourg, France

Paris, France and 4 other locations

effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...

Active, not recruiting
Multiple Sclerosis
Drug: Dexchlorpheniramine
Drug: Methylprednisolone

Phase 3

Genzyme
Genzyme

Le Kremlin Bicetre, France and 20 other locations

Treating cognitive impairment (CI) in multiple sclerosis (MS), the leading cause of disability due to nontraumatic neurolo...

Enrolling
Multiple Sclerosis
Other: Telerehabilitation : active procedure
Behavioral: Patent reported outcomes (PRO's)
University Hospital of Bordeaux

Poissy, France and 6 other locations

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Le Kremlin Bicêtre cedex, Val De Marne, France and 64 other locations

study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...

Active, not recruiting
Multiple Sclerosis
Drug: Ofatumumab
Drug: First line DMT

Phase 3

Novartis
Novartis

Creteil, France and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems